Renal_JJ
cell_NN
carcinoma-derived_JJ
gangliosides_NNS
suppress_VBP
nuclear_JJ
factor-kappaB_NN
activation_NN
in_IN
T_NN
cells_NNS
._.

Activation_NN
of_IN
the_DT
transcription_NN
factor_NN
nuclear_JJ
factor-kappaB_NN
-LRB-_-LRB-
NFkappaB_NN
-RRB-_-RRB-
is_VBZ
impaired_JJ
in_IN
T_NN
cells_NNS
from_IN
patients_NNS
with_IN
renal_JJ
cell_NN
carcinomas_NNS
-LRB-_-LRB-
RCCs_NNS
-RRB-_-RRB-
._.

In_IN
circulating_VBG
T_NN
cells_NNS
from_IN
a_DT
subset_NN
of_IN
patients_NNS
with_IN
RCCs_NNS
,_,
the_DT
suppression_NN
of_IN
NFkappaB_NN
binding_NN
activity_NN
is_VBZ
downstream_JJ
from_IN
the_DT
stimulus-induced_JJ
degradation_NN
of_IN
the_DT
cytoplasmic_JJ
factor_NN
IkappaBalpha_NN
._.

Tumor-derived_JJ
soluble_JJ
products_NNS
from_IN
cultured_VBN
RCC_NN
explants_NNS
inhibit_VBP
NFkappaB_NN
activity_NN
in_IN
T_NN
cells_NNS
from_IN
healthy_JJ
volunteers_NNS
,_,
despite_IN
a_DT
normal_JJ
level_NN
of_IN
stimulus-induced_JJ
IkappaBalpha_NN
degradation_NN
in_IN
these_DT
cells_NNS
._.

The_DT
inhibitory_JJ
agent_NN
has_VBZ
several_JJ
features_NNS
characteristic_JJ
of_IN
a_DT
ganglioside_NN
,_,
including_VBG
sensitivity_NN
to_TO
neuraminidase_NN
but_CC
not_RB
protease_NN
treatment_NN
;_:
hydrophobicity_NN
;_:
and_CC
molecular_JJ
weight_NN
less_JJR
than_IN
3_CD
kDa_NN
._.

Indeed_RB
,_,
we_PRP
detected_VBD
gangliosides_NNS
in_IN
supernatants_NNS
from_IN
RCC_NN
explants_NNS
and_CC
not_RB
from_IN
adjacent_JJ
normal_JJ
kidney_NN
tissue_NN
._.

Gangliosides_NNS
prepared_VBN
from_IN
RCC_NN
supernatants_NNS
,_,
as_RB
well_RB
as_IN
the_DT
purified_VBN
bovine_JJ
gangliosides_NNS
G_NN
-LRB-_-LRB-
m1_NN
-RRB-_-RRB-
and_CC
G_NN
-LRB-_-LRB-
d1a_NN
-RRB-_-RRB-
,_,
suppressed_VBD
NFkappaB_NN
binding_NN
activity_NN
in_IN
T_NN
cells_NNS
and_CC
reduced_VBD
expression_NN
of_IN
the_DT
cytokines_NNS
IL-2_NN
and_CC
IFN-gamma_NN
._.

Taken_VBN
together_RB
,_,
our_PRP$
findings_NNS
suggest_VBP
that_IN
tumor-derived_JJ
gangliosides_NNS
may_MD
blunt_VB
antitumor_JJ
immune_JJ
responses_NNS
in_IN
patients_NNS
with_IN
RCCs_NNS
._.

